1.	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA204-004, 2010-020347-12, NCT01239797
2.	A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HuLuc63-1703, 2007-006677-83, NCT00742560
3.	Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HuLuc63-1701, FHCRC-2127.00, PDL-HuLuc63-1701, NCT00425347
4.	Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA204-005, NCT01241292
5.	Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Enrolling by invitation Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA204-007, NCT01393964